Acute life-threatening toxicity of cancer treatment.
Although patients with cancer may derive much benefit from treatment, they are at risk for developing life-threatening complications. Hypersensitivity reactions can be severe, as in the case of anaphylaxis with L-asparaginase. Cardiac toxicities consist of arrhythmias with various drugs, hemorrhagic myocarditis with cyclophosphamide and ifosfamide, cardiomyopathy with anthracyclines, and pericardial disease. Acute respiratory failure may occur as a result of ARDS caused by ATRA or cytarabine, from interstitial fibrosis, or from pulmonary veno-occlusive disease. Hemorrhagic cystitis caused by cyclophosphamide and ifosfamide can be severe and result in exsanguination if unresponsive to treatment. Disseminated intravascular coagulation and thrombotic microangiopathy can produce thrombotic or hemorrhagic complications. Gastrointestinal toxicities include significant hepatotoxicity with a variety of drugs and development of acute surgical abdomen.
Shanholtz
C
C
Department of Medicine, Divisions of Pulmonary and Critical Care Medicine and Hematology and Medical Oncology, University of Maryland School of Medicine, Baltimore, USA. cshanhol@medicine.umaryland.edu
D000970:Antineoplastic Agents / Q000009:adverse effects*; D003556:Cystitis / Q000139:chemically induced; D004342:Drug Hypersensitivity; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006331:Heart Diseases / Q000139:chemically induced; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents